Plain-English translation of NCT06411249 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a 3-year study testing belimumab, an injectable medication designed to help people with early systemic lupus erythematosus (SLE) who are not getting enough relief from standard treatments. Researchers want to understand how well and how safely this medication works when given by injection under the skin. About 300 adults with early lupus will participate.
Many people with lupus don't improve enough with first-line treatments alone, and they need additional options. This study is designed to see whether this medication can safely reduce disease activity and help people feel better over the long term.
You will receive injections of the new medication under your skin on a regular schedule over the 3-year study period. You will have multiple visits to the clinic for blood tests, physical exams, and assessments of how your lupus is responding. The study team will monitor you closely for both how well the medication works and any side effects, with visits becoming less frequent after the first year.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
United States